Royalty Report: Drugs, Cancer, HIV / AIDs – Collection: 361677

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 17

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 17

Primary Industries

  • Drugs
  • Cancer
  • HIV / AIDs
  • Disease
  • Viral Infection
  • Antibody
  • Pharmaceuticals
  • Therapeutic
  • Biotechnology
  • Drug Discovery
  • Drug Testing
  • DNA
  • Herpes
  • Wound Care
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 361677

License Grant
Licensor assigned to Licensee in the Progenics Purchase Agreement, pursuant to which we have an exclusive worldwide license to develop, make, have made, import, use, sell, offer to sell or have sold products that incorporate the humanized form of the leronlimab antibody developed under the agreement.
License Property
Leronlimab, a monoclonal antibody C—C chemokine receptor type 5 (“CCR5”) receptor antagonist, to be used as a platform drug for various indications. The target of leronlimab is the immunologic receptor CCR5. The CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. On white blood cells, it serves as a receptor for chemical attractants called chemokines. The CCR5 receptor is also the co-receptor needed for certain strains of HIV to infect healthy T-cells. Recent research has identified the CCR5 receptor as an important target for many disease processes, including cancer metastasis and certain immunological conditions. Leronlimab is a unique humanized monoclonal antibody.

Leronlimab binds to the second extracellular loop and N-terminus of the CCR5 receptor, and due to its selectivity and target-specific mechanism of action, leronlimab does not appear to activate the immune function of the CCR5 receptor through agonist activity. This apparent target specificity differentiates leronlimab from other CCR5 antagonists. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor.

Field of Use
Leronlimab (PRO 140) is a CCR5 antagonist with the potential for multiple therapeutic indications, today provided an update on leronlimab (PRO140) as a single agent for maintenance of HIV viral load suppression (HIV-1 RNA < 50 copies/mL).

The latest investigative monotherapy trial has revealed sufficient data to more precisely design the pivotal Phase 3 monotherapy trial that Licensee plans to use as the basis for label expansion after the potential approval of leronlimab (PRO140) for HIV patients as a combination therapy with HAART.  The longer half-life of leronlimab may help to reduce the number of non-responders in the first ten weeks of monotherapy, if the treatment overlaps with existing regimen of leronlimab for four weeks before initiating monotherapy.  Under the current trial protocol, patients have 7 days of overlap with their HAART regimen and leronlimab before initiating monotherapy.

The U.S. Food and Drug Administration (FDA) has granted a “Fast Track” designation to leronlimab (PRO 140) as a combination therapy with HAART for HIV-infected patients.  Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that appears to play multiple roles with implications in HIV infection, tumor metastases and immune signaling.  Leronlimab (PRO 140) has successfully completed nine Phase 1/2/3 clinical trials in over 700 people, including a successful pivotal Phase 3 trial in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients.

Field of use is to treat human immunodeficiency virus (“HIV”) patients with multiple resistance to current standard of care, COVID-19 patients, and metastatic Triple Negative Breast Cancer (“mTNBC”), among other indications.

IPSCIO Record ID: 322463

License Grant
Licensor sold Leronlimab to Licensee where Licensee is responsible for all development, manufacturing and commercialization efforts.
License Property
Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including certain liver diseases.

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control.  Blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer.

Field of Use
The field of use is for the treatment in HIV infection, tumor metastases, and other diseases including certain liver diseases.

HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection.
Metastasis means that cancer spreads to a different body part from where it started.
Liver cancer is the growth and spread of unhealthy cells in the liver.

Licensee is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.

IPSCIO Record ID: 289819

License Grant
Licensor hereby grants to Licensee an exclusive royalty-bearing license (or sublicense, as the case may be), under the Licensor Patents, the Licensor  Know-How and the Inventions (if any) solely to Commercialize, use, have used, offer for sale and sell Licensed Products in the Field in the Territory.

With this agreement, Licensor will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications, while Licensee has been granted an exclusive license to market and distribute leronlimab.

License Property
Leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.

Licensor has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (“HIV”) infection, as well as related HIV infection indications.

Field of Use
The field of use is for the treatment of HIV.

IPSCIO Record ID: 56027

License Grant
The Company acquired the rights to the HIV viral-entry inhibitor drug candidate PRO 140, a humanized anti-CCR5 monoclonal antibody, as well as certain other related assets, including the existing inventory of bulk PRO 140 drug product, intellectual property, certain related licenses and sublicenses, and U.S. Food and Drug administration regulatory filings.
License Property
PRO 140 belongs to a class of HIV therapies known as entry inhibitors. These therapies block HIV from entering into and infecting certain cells. We believe that monoclonal antibodies are a new emerging class of therapeutics for the treatment of HIV. Seven clinical trials demonstrating safety and efficacy for PRO 140 have been completed.
Field of Use
The rights granted apply to the drug industry.

IPSCIO Record ID: 139546

License Grant
The Canadian Company reacquired the 50% interest in the Antibody 1F7 acquired by Licensor.
License Property
The monoclonal antibody 1F7 has several important effects on both humoral (antibody-mediated) and cellular immunity mechanisms  that make it an ideal candidate for an HIV therapy.  The anti-idiotypic antibody 1F7 selectively inhibits cytotoxic T-cells activated in HIV-1 infection.  Immunol Cell Biol 78(1), 20-7.
Field of Use
This agreement pertains to the drug industry related to its use as a therapeutic for the prevention and treatment of HIV infection.

IPSCIO Record ID: 26237

License Grant
The agreement granted exclusive development and commercialization rights to the Licensor's fully human, immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014 for the greater Chinese market.
License Property
The mAb is novel, proprietary, and fully human. The Licensor is currently developing production quality cell lines for their anti-PD-L1 antibody, STI-A1010, which will lay the foundation for Investigational New Drug, or IND, -enabling studies in the U.S. in 2014. The Licensor anticipates that a Phase I clinical trial for their lead candidate anti-PD-L1 antibody could be initiated in 2015.  The mAb's are derived from the Licensor's proprietary G-MAB® library platform and chosen based on cancer targets.

Patent Antigen binding proteins that bind PD-L1

Field of Use
The individual mAbs discovered from the Licensor's library potentially give a multitude of therapeutic options to target and attack cancer cells. This could be either directly, such as (i) recruitment of immune effector functions, including, but not limited to, antibody-dependent cellular cytotoxicity, or ADCC, or (ii) antagonistic suppression of cellular signaling processes required for cancer proliferation and metastasis; or indirectly, via modulation host biology, such as (a) enhancement of immune activity in the tumor, or (b) normalization of the tumor microenvironment, including anti-angiogenesis for cutting off blood supplies to the tumor.

IPSCIO Record ID: 256218

License Grant
The Licensor of Israel grants an exclusive, worldwide royalty bearing license, with the right to grant sublicenses through multiple tiers,  under the Licensed IP Rights to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, import, export, commercialize and otherwise exploit Licensed Products for use in the Field.
License Property
The licensed patents refer to Chimeric Receptor Genes and Cells Transformed Therewith.

Eshhar patents US 5,906,936
US 7,741,465, Eshhar et al

Eshhar-NIH patent US 8,211,422, Eshhar et al

Eshhar-NIH pending application [US 13/281,560, Eshhar et al

KTE-C19 is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias.

Field of Use
The Field shall mean, collectively, all oncology applications and all other applications, as mutually agreed in writing by the parties and attached as an amendment to this Agreement.

IPSCIO Record ID: 302213

License Grant
Licensor granted to Chinese Licensee an exclusive, sublicensable, royalty-bearing license to Licensor’s patents and know-how to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement.
License Property
Enoblituzumab is the Most Advanced Clinical Stage Humanized B7-H3 Antibody as a Potential Immuno-oncology Treatment.  This is a Fc-optimized antibody that targets B7-H3, including in combination with other agents, such as the anti-PD-1 antibody known as MGA012.

Enoblituzumab is a humanized antibody directed at B7-H3, a member of the B7 family of T cell checkpoint regulators. B7-H3 is a promising immuno-oncology drug target as it is widely expressed across multiple tumor types and plays a key role in regulating immune response against cancers. Increasing pre-clinical and clinical evidence suggests that antibodies targeting the two T cell checkpoint molecules—B7-H3 and PD-1—work synergistically in treating cancer. Given B7-H3’s critical role, enoblituzumab has a wide range of cancer applications as either a monotherapy or in combination with PD-1 therapies. At the molecular level, enoblituzumab is engineered to possess an enhanced anti-tumor ADCC function and is at the forefront in global clinical development. Originally developed by Licensor, enoblituzumab has been evaluated in multiple clinical trials as a monotherapy or in combination with CTLA-4 or PD-1 therapies in patients with B7-H3-expressing cancers. Enoblituzumab is also being evaluated in a neoadjuvant Phase 2 study as a single agent in patients with intermediate and high-risk localized prostate cancer.

Field of Use
The license granted is used as an immuno-oncology drug target playing a key role in regulating immune response against cancers.

Licensee and its subsidiaries are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China (the “PRC”) and other countries and regions.

IPSCIO Record ID: 27803

License Grant
Licensor grants the Swiss Licensee, an exclusive, non-transferable  license or sublicense, as applicable, under the Licensor IP to Develop, Manufacture and Commercialize Licensed Antibodies and Products in the Territory and in the Field.

The Licensor and the Licensee formed a global alliance focused on novel immuno-therapeutics using the Licensor's proprietary Retrocyte Displayâ„¢ antibody discovery platform. The collaboration is initially focused on the development of checkpoint modulator antibodies directed against GITR, OX40, LAG-3 and TIM-3.

License Property
The Licensor is an immunology company developing a series of Checkpoint Modulators for the treatment of patients with cancer, infectious diseases, and other immune disorders, heat shock protein (HSP)-based vaccines, and immune adjuvants.

LAG-3 is a checkpoint protein expressed on the surface of certain cells of the immune system. LAG-3 (lymphocyte-activation gene 3) modulates signaling between immune cells and their targets. When LAG-3 is activated, the immune response is suppressed. Antibodies that block LAG-3 can block this inhibitory signal, thereby boosting the immune system’s response against cancer cells. LAG-3 acts synergistically with other checkpoint modulators. This suggests antibodies against LAG-3 may be valuable as combination therapies.

TIM-3 is a checkpoint receptor found on certain immune cells. TIM-3 stands for T-cell immunoglobulin and mucin domain-3. To prevent hyperactivation, natural ligands binding to TIM-3 reduce the activity of these immune cells. In some types of cancer, T cells express elevated levels of TIM-3, which results in excessive immune suppression. Blocking TIM-3 could stimulate immune responses and promote immune-mediated clearing of cancer cells. TIM-3 antibodies may have a role as a monotherapy and hold great potential in combination therapy, since they may help overcome resistance that patients may develop against other therapeutics.

[U.S. Patent Application Serial No. 62/004,071, filed May 28, 2014, entitled 'Anti-GITR Antibodies and Methods of Use Thereof.']
Field of Use
The Parties are interested in forming an alliance whose goal is to discover, develop and commercialize a robust portfolio of products to address hematologic and oncologic diseases or conditions.

Checkpoint antibodies effect the immune system, and are now being used in cancer treatment.

The Field means any use of Antibodies for the treatment, control, mitigation, prevention or cure of any or all Indications in humans or animals in the Hematology Field and the Oncology Field

IPSCIO Record ID: 118355

License Grant
The Licensors, including a University, granted a worldwide, exclusive license to commercialize and exploit natural hypericin and synthetic hypericin compounds to inactivate viruses and retroviruses as a therapeutic or preventive treatment for viral or retroviral diseases, and for anti-glioma, meaning brain tumor, indications.
License Property
Hypericin is a chemically synthesized analog of St. Johns wort.

VIMRxyn(R) is comprised of chemically synthesized hypericin and, in laboratory tests, has inhibited the infection of normal cells by targeted viruses. Hypericin is an aromatic polycyclic dione found in the stem and petals of the common Saint John's wort, a plant which has been used as a folk remedy since the Middle Ages. Hypericin plant extracts continue to be used as lay treatments for various disorders. The Company is investigating utilizing VIMRxyn as a treatment for viral and retroviral diseases, including the human immune deficiency virus ('HIV'), which is the retrovirus responsible for Acquired Immune Deficiency Syndrome ('AIDS'), and also is investigating utilizing VIMRxyn as a treatment for hepatitis C, as a therapeutic for brain cancer (glioma), and as a means of inactivating HIV and other lipid-enveloped viruses in blood collected for transfusions.

Field of Use
The field of use is for treatment of glioblastoma multiforme, a serious form of brain cancer, among other diseases.

IPSCIO Record ID: 359135

License Grant
Licensor entered into a license agreement with Chinese Licensee, thereby granting to Licensee exclusive rights to commercialize Licensor's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America.
License Property
Pritumumab, a drug candidate using monoclonal antibodies for the treatment of various cancer types. Pritumumab may offer an advantage over existing treatments. Pritumumab works by binding to a target on the surface of cancer cells called ectodomain vimentin (also referred to as cell-surface vimentin). The target, generally referred to as an antigen, is prevalent in many different tumor types and is not being targeted by any other biopharmaceutical companies. By binding to this target, Pritumumab is able to make the tumor cells “known” to the body’s immune system, resulting in potentially several types of immune responses, including anti-idiotype, apoptosis, antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to death of the cancer cells and overall depletion of the tumor.
Field of Use
Field of use is for the treatment of brain cancer and pancreatic cancer and exploring in its use against viruses.

IPSCIO Record ID: 365329

License Grant
This amendment, included with this agreement, updates the financial terms, including the royalty rates.

By the original agreement, University grants to an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale University Licensed Products.

This license grant is exclusive with respect to Universitys rights, except that University may use and permit other nonprofit organizations to use the University Patent Rights for educational and research purposes and not for sale or offer of sale.

License Property
The University controls certain intellectual property developed related to pathogenic viral proteins which control host cell functions.
Field of Use
Licensee is a biopharmaceutical company engaged in the discovery and development of drugs and DNA vaccines for the treatment of infectious diseases, including the HIV and hepatitis C viruses, as well as cancer and inflammatory diseases.

IPSCIO Record ID: 362516

License Grant
The University grants to an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale University Licensed Products.

This license grant is exclusive with respect to Universitys rights, except that University may use and permit other nonprofit organizations to use the University Patent Rights for educational and research purposes and not for sale or offer of sale.

License Property
The University controls certain intellectual property developed related to pathogenic viral proteins which control host cell functions.
Field of Use
Licensee is a biopharmaceutical company engaged in the discovery and development of drugs and DNA vaccines for the treatment of infectious diseases, including the HIV and hepatitis C viruses, as well as cancer and inflammatory diseases.

IPSCIO Record ID: 1395

License Grant
Licensor hereby grants, and Licensee hereby accepts, the following licenses

(a) an exclusive, worldwide license, including the right to grant sublicenses, to develop, make, have made, import, use, sell, offer to sell or have sold Licensed Products and related cell lines, including the Sp2/0 Cell Line.

License Property
Licensor has developed a murine monoclonal antibody directed against the CCR5 antigen and designated by Licensee's as “PRO 140”

“Humanized Antibody(ies)” means the humanized form of the Murine Antibody.

“Licensed Product(s)” means products, for any use, incorporating substantially all of the Humanized Antibody or any modification, variant or fragment of the Humanized Antibody containing at least one variable region of the Humanized Antibody.

“Murine Antibody(ies)” means, subject to Section 2.01(b), the murine monoclonal antibody designated as “PRO 140” directed against the Target Antigen.

Field of Use
Licensee shall also evaluate the Humanized Antibody to determine whether such antibody also possesses anti-HIV activity not less than one-third (1/3) that of the Murine Antibody (“Minimum Anti-HIV Activity”) as measured according to an HIV-1 infectivity assay that measures the extent of HIV-l replication.

IPSCIO Record ID: 344581

License Grant
The University grants a worldwide, exclusive license under Licensed Subject Matter to manufacture, have manufactured, use, import, offer for sale and/or sell Licensed Products for use within Field.
License Property
The University owns certain Patent Rights and Technology Rights related to Licensed Subject Matter.

The licensed patents include
— Antibodies and Peptides Binding to Anionic Phospholipids and Aminophospholipids and Their Use in Viral Inhibition & Disease Treatment,
— Methods For Treating Viral Infections Using Antibodies To Aminophospholipids,
— Combinations and Kits for Treating Viral Infections Using Antibodies to Aminophospholipids,
— Methods for Treating Viral Infections Using Immunoconjugates to Aminophospholipids,
— Compositions for Treating Viral Infections Using lmmunoconjugates to Aminophospholipids,
— Combinations and Kits for Treating Viral Infections Using Immunoconjugates To Aminophospholipids,
— Selected Antibodies and Duramycin Peptides Binding to Anionic Phospholipids and Aminophospholipids and Their Use in Treating Viral Infections and Cancer,
— Selected Antibody Compositions For Binding To Aminophospholipids,
— Selected Antibody Compositions and Methods For Binding To Aminophospholipids,
— Cancer Treatment Methods Using Selected Antibodies to Aminophospholipids,
— Combined Cancer Treatment Methods Using Selected Antibodies to Aminophospholipids,
— Selected Antibody CDRs for Binding To Aminophospholipids,
— Liposomes Coated with Selected Antibodies That Bind to Aminophospholipids,
— Combinations and Kits For Cancer Treatment Using Selected Antibodies to Aminophospholipids,
— Selected Immunoconjugates for Binding To Aminophospholipids,
— Cancer Treatment Methods Using Selected Immunoconjugates For Binding To Aminophospholipids,
— Selected Antibodies & Duramycin Peptides Binding to Anionic Phospholipids & Aminophospholipids &
Their Use in Treating Viral Infections & Cancer,
— Compositions Comprising Cell-Impermeant Duramycin Derivatives,
— Anti-Viral Treatment Methods Using Phosphatidylethanolamine-Binding Peptide Derivatives,
— Compositions Comprising Phosphatidylethanolamine-Binding Peptides Linked to Anti-Viral Agents, and,
— Anti-Viral Treatment Methods Using Phosphatidylethanolamine-Binding Peptides Linked to Anti-Viral Agents.

Field of Use
The Field means all human therapeutic and diagnostic uses; and the treatment of viral infections and cancer.

IPSCIO Record ID: 322039

License Grant
The parties collaborated to globally develop and commercialize Licensor’s ladiratuzumab vedotin (MK-6440). The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors.

Licensor granted Licensee an exclusive license to commercialize Tukysa (tucatinib) for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Licensor will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Licensor will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan.

License Property
Ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors.

Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor to treat a type of breast cancer.

HER2-positive cancers is a protein that can promote the growth of breast cancer cells. Breast cancer cells with high levels of HER2 are called HER2-positive.

Licensor is a biotechnology company that study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases including cancer.

Field of Use
The field of use is for the treatment of cancer such as breast cancer.

HER2-positive breast cancer is a type of breast cancer in which breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2).

Licensee is a premier research-intensive biopharmaceutical company that researches medicines and vaccines to prevent and treat diseases including cancers.

IPSCIO Record ID: 4361

License Grant
Licensor hereby grants to Licensee an exclusive worldwide license, with the right to grant sublicensed, in all fields under the Licensed patents, to make, have made, use, sell, offer for sale and import Licensed Products and to use Licensed Products.
License Property
Licensor is the owner by assignment of certain intellectual property relating to the treatment with opioid antagonists (such as naltrexone) and (met-enkephalin), alone or in combination with standard of care treatments, of a variety of diseases and conditions, including multiple sclerosis, cancer of the prostate, Lymphoproliferative syndrome, including such diseases as malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, is treated in human patients by the administration, chronic herpes virus infections, chronic herpes viral infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, and chronic infections due to the Epstein-Barr virus, chronic, A treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS, those suffering from AIDS-related complex (ARC).  In particular, the inventions relate to methods and formulations for treatment of these conditions, including but not limited to all INDs, communications with regulatory agencies, patient data, and letters relating to the intellectual property.

The Intellectual Property relates to treatments with opioid antagonists such as naltrexone and et-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC).

Licensed Patents
U.S. Patent Number 6,586,443
U.S. Patent Number 6,384,044
U.S. Patent Number 6,288,074
U.S. Patent Number 5,356,900
U.S. Patent Number 5,013,739
U.S. Patent Number 4,888,346

Field of Use
The Licensee's most advanced clinical programs involve immunotherapy using Met-enkephalin (“MENK”) and low dose naltrexone (“LDN”). Both immunotherapies work by triggering opioid receptors on immune cells leading to an activation and expansion of various cells of the immune system.

In clinical trials, MENK has been shown to reduce early AIDS and AIDS Related Complex, a condition also known as pre-AIDS which include symptoms such as fever, diarrhea, weight loss, swollen lymph nodes and herpes.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.